Titre : Cytochrome P-450 CYP1B1

Cytochrome P-450 CYP1B1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Biometry
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes", "headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-12", "dateModified": "2025-03-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Famille-1 de cytochromes P450", "url": "https://questionsmedicales.fr/mesh/D000072461", "about": { "@type": "MedicalCondition", "name": "Famille-1 de cytochromes P450", "code": { "@type": "MedicalCode", "code": "D000072461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453.100" } } }, "about": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1", "alternateName": "Cytochrome P-450 CYP1B1", "code": { "@type": "MedicalCode", "code": "D065633", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Purnima Singh", "url": "https://questionsmedicales.fr/author/Purnima%20Singh", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Shubha Ranjan Dutta", "url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Chi Young Song", "url": "https://questionsmedicales.fr/author/Chi%20Young%20Song", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Frank J Gonzalez", "url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez", "affiliation": { "@type": "Organization", "name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)." } }, { "@type": "Person", "name": "Kafait U Malik", "url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Similarity of eyes in a cataractous population-How reliable is the biometry of the fellow eye for lens power calculation?", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/35771869", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0269709" } }, { "@type": "ScholarlyArticle", "name": "Fetal brain biometry and cortical development in congenital heart disease: A prospective cross sectional study.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36069371", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcu.23308" } }, { "@type": "ScholarlyArticle", "name": "Spherical Aberration of Cataractous Eyes and Its Relationship With Age, Ocular Biometry, and Various IOL Platforms.", "datePublished": "2023-02-01", "url": "https://questionsmedicales.fr/article/36779463", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/1081597X-20221207-01" } }, { "@type": "ScholarlyArticle", "name": "Impact and Correction of an Anterior Phakic Intraocular Lens on Swept-Source Optical Coherence Tomography Biometry.", "datePublished": "2024-08-01", "url": "https://questionsmedicales.fr/article/39120018", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/1081597X-20240716-01" } }, { "@type": "ScholarlyArticle", "name": "Fetal biometry and amniotic fluid volume assessment end-to-end automation using Deep Learning.", "datePublished": "2023-11-03", "url": "https://questionsmedicales.fr/article/37923713", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-42438-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Hémoprotéines", "item": "https://questionsmedicales.fr/mesh/D006420" }, { "@type": "ListItem", "position": 5, "name": "Cytochromes", "item": "https://questionsmedicales.fr/mesh/D003580" }, { "@type": "ListItem", "position": 6, "name": "Cytochrome P-450 enzyme system", "item": "https://questionsmedicales.fr/mesh/D003577" }, { "@type": "ListItem", "position": 7, "name": "Famille-1 de cytochromes P450", "item": "https://questionsmedicales.fr/mesh/D000072461" }, { "@type": "ListItem", "position": 8, "name": "Cytochrome P-450 CYP1B1", "item": "https://questionsmedicales.fr/mesh/D065633" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cytochrome P-450 CYP1B1", "description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cytochrome P-450 CYP1B1", "description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cytochrome P-450 CYP1B1", "description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cytochrome P-450 CYP1B1", "description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cytochrome P-450 CYP1B1", "description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1", "description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de CYP1B1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer CYP1B1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec CYP1B1 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction." } }, { "@type": "Question", "name": "Le diagnostic de CYP1B1 est-il complexe ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une mutation de CYP1B1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 varient-ils selon les individus ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation." } }, { "@type": "Question", "name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à CYP1B1 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à CYP1B1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut le dépistage génétique et l'éducation sur les risques." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il CYP1B1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il important pour CYP1B1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les complications." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives." } }, { "@type": "Question", "name": "Quels traitements existent pour les troubles liés à CYP1B1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques." } }, { "@type": "Question", "name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs pour CYP1B1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon la gravité de la condition." } }, { "@type": "Question", "name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec CYP1B1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être graves et nécessiter une intervention médicale." } }, { "@type": "Question", "name": "Comment gérer les complications liées à CYP1B1 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles avec un suivi approprié." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme avec CYP1B1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour CYP1B1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles." } }, { "@type": "Question", "name": "L'exposition à des toxines influence-t-elle CYP1B1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1." } }, { "@type": "Question", "name": "Le sexe influence-t-il les risques liés à CYP1B1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1." } }, { "@type": "Question", "name": "L'alimentation a-t-elle un impact sur CYP1B1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme." } } ] } ] }

Sources (412 au total)

Similarity of eyes in a cataractous population-How reliable is the biometry of the fellow eye for lens power calculation?

In some situations it is necessary to use biometry from the fellow eye for lens power calculation prior to cataract surgery. The purpose of this study was to analyse the lateral differences in biometr... The analysis was based on a large dataset of 19,472 measurements of 9736 patients prior to cataract surgery with complete biometric data of both left and right eyes extracted from the IOLMaster 700. A... Lateral differences (S-P, 90% confidence interval) ranged between -0.64 to 0.63 dpt / -0.67 to 0.66 dpt / -0.12 to 0.12 dpt for RSEQ / TRSEQ / BRSEQ. The respective difference in AL / CCT / ACD / LT r... Despite a strong similarity of both eyes, intraocular lens power calculation with fellow eye biometry could yield different results for the lens power and finally for the predicted refraction. In 10% ...

Fetal brain biometry and cortical development in congenital heart disease: A prospective cross sectional study.

To evaluate brain biometry and cortical development by neurosonography in fetuses with congenital heart defect (CHD) and evaluate differences among different type of CHD.... In a prospective cross sectional study singleton fetus with CHD were matched with controls and grouped into two categories according to the predicted severity of cerebral arterial oxygen deficit induc... A total of 78 fetuses with CHD (group A 30; group B 48) and 80 matched controls form uncomplicated pregnancies were considered. CHD fetuses have significantly smaller CC, CV, SF, and POF and bigger in... Fetuses with CHD have an impaired cortical development and these variations are more evident in those with a predicted lower oxygen delivery to the brain....

Spherical Aberration of Cataractous Eyes and Its Relationship With Age, Ocular Biometry, and Various IOL Platforms.

To determine the median spherical aberration (SA) of the cataractous population, how it relates to biometry, and the theoretical effect of different intraocular lens (IOL) platforms.... A retrospective chart review of patients undergoing cataract surgery evaluation with a high quality Pentacam (Oculus Optikgeräte GmbH) were included. Age, gender, Q-value, mean total SA, higher order ... Data from 1,725 eyes of 999 patients were collected. SA had a median of 0.37 µm (95% confidence interval: 0.36 to 0.38. Age (... SA is not normally distributed, suggesting that there may be no "average" SA that IOLs should aim to correct. Patients might benefit from tailoring IOL choice to individual SA. Without access to SA da...

Impact and Correction of an Anterior Phakic Intraocular Lens on Swept-Source Optical Coherence Tomography Biometry.

To evaluate the impact of anterior chamber phakic intraocular lens (pIOL) on swept-source optical coherence tomography (SS-OCT) biometric measurements and IOL power calculation.... This retrospective analysis of 67 eyes of 49 patients with previous anterior chamber pIOL implantation analyzed the accuracy of automatic segmentation of the anterior surface of the crystalline lens a... The anterior surface of the crystalline lens was mis-identified in 13 (19.4%) eyes. ACD was underestimated (Δ -0.85 ± 0.33 mm,... SS-OCT biometry misidentifies the anterior surface of the crystalline lens in a significant proportion, resulting in significant IOL power calculation error in the Haigis formula. Manual proofing of s...

Biometry and Intraocular Lens Power Calculation in Eyes with Prior Laser Vision Correction (LVC) - A Review.

An intraocular lens (IOL) calculation in eyes that have undergone laser vision correction (LVC) poses a significant clinical issue in regards to both patient expectation and accuracy. This review aims... Problems after LVC derive from the measurement of anterior corneal radii, central corneal thickness, asphericity, and the predicted effective lens position. A central issue is that most conventional 3... An IOL power calculation results in eyes with prior LVC that are notably impaired in eyes without prior surgery. Effective corneal power including anterior corneal curvature, posterior corneal curvatu...

Optical Biometry and IOL Calculation in a Commercially Available Optical Coherence Tomography Device and Comparison With Pentacam AXL.

Optical devices are the gold standard for ocular biometry; however, they are unable to obtain high-quality optical coherence tomography (OCT) images. The current study aimed to evaluate ocular measure... Prospective evaluation of a diagnostic tool.... This study enrolled healthy subjects at the Hygeia Clinic, Gdańsk, Poland, between October 2021 and November 2021. All individuals had ocular biometry measured with a validated biometer (Pentacam AXL)... The mean age of the 144 participants was 25.23 ± 7.15 years. The axial length measured with Revo was longer than with Pentacam AXL (24.08 ± 1.13 vs 23.98 ± 1.13; P < .0001), a 0.10 ± 0.04 mm differenc... The present study demonstrates that the results of IOL calculation with the OCT biometer have a very strong correlation with those obtained with the Pentacam AXL; however, axial length measurements an...

Combining deep learning and intelligent biometry to extract ultrasound standard planes and assess early gestational weeks.

To develop and validate a fully automated AI system to extract standard planes, assess early gestational weeks, and compare the performance of the developed system to sonographers.... In this three-center retrospective study, 214 consecutive pregnant women that underwent transvaginal ultrasounds between January and December 2018 were selected. Their ultrasound videos were automatic... The standard planes were extracted with an AUC of 0.975, a sensitivity of 0.961, and a specificity of 0.979. The gestational sacs' contours were segmented with a mDice of 0.974 (error less than 2 pixe... This proposed end-to-end tool allows automatic assessment of gestational weeks in early pregnancy and may reduce manual analysis time and measurement errors.... The fully automated tool achieved high accuracy showing its potential to optimize the increasingly scarce resources of sonographers. Explainable predictions can assist in their confidence in assessing... • The end-to-end pipeline enabled automatic identification of the standard plane containing the gestational sac in an ultrasound video, as well as segmentation of the sac contour, automatic multi-angl...

Repeatability and reproducibility of the galilei G6 and its agreement with the pentacam® AXL in optical biometry and corneal tomography.

To assess the repeatability and reproducibility of corneal measurements performed by the Galilei G6 and determine its agreement with the Pentacam® AXL.... 105 eyes underwent examination by both devices, measuring nine parameters. Paired t-tests, Deming Regression, and Bland-Altman plots were used to determine agreement. Analysis of Variance was used to ... Measurements showed no clinically significant differences between the two devices. On average, the Galilei G6 measured axial length longer than the Pentacam® AXL by 0.05 mm ± 0.03 mm (p < 0.001), just... The Galilei G6 and Pentacam® AXL measurements show evidence of repeatability, reproducibility, and agreement for examined parameters. Certain caution needs to be applied in cases with moderate or seve...

Effect of magnet strength on fetal brain biometry - a single-center retrospective MRI-based cohort study.

Abnormal fetal brain measurements might affect clinical management and parental counseling. The effect of between-field-strength differences was not evaluated in quantitative fetal brain imaging until... A retrospective cohort of 1150 low-risk fetuses scanned between 2012 and 2021, with apparently normal brain anatomy, were retrospectively evaluated for biometric measurements. The cohort included 1.5 ... No significant differences between centiles of bi-parietal diameter, trans-cerebellar diameter, or length of the corpus callosum between 1.5 T and 3.0 T scanners were found. Small absolute differences... The increasing use of 3.0 T MRI for fetal imaging poses a potential bias when using 1.5 T-based charts. We elucidate those biometric measurements are comparable, with relatively small between-field-st...